MIL93 — Investigational Agent
Monoclonal Antibody · Phase 1 · Beijing Mabworks Biotech
Mechanism of Action
MIL93 is a recombinant humanized monoclonal antibody targeting Claudin18.2 on gastric and pancreatic tumor cells, eliciting ADCC and CDC against CLDN18.2-expressing malignancies. Its glyco-engineered Fc is designed to enhance effector-cell killing.
Investigational Indications
- CLDN18.2-positive gastric/GEJ adenocarcinoma
- Pancreatic adenocarcinoma